Issue link: https://www.e-digitaleditions.com/i/1497323
PharmTech.com The Real Message Behind Commercial mRNA Products April eBook 2023 Pharmaceutical Technology ® 49 AnAly tics Man‑Made Single‑Stranded RNAs. Sci. Rep. 2019, 9 (1), 1019. DOI:10.1038/s41598‑018‑37642‑z 31. Currie, J.; Dahlberg, J. R.; Eriksson, J.; et al. Stability Indi‑ cating Ion‑Pair Reversed‑Phase Liquid Chromatography Method for Modified mRNA. ChemRxiv Cambridge: Cam‑ bridge Open Engage. 2021. 32. DeLano, M.; Walter, T. H.; Lauber, M. A.; et al. Using Hy br id O r g a n ic‑I nor g a n ic Su r f a ce Te c h nolog y t o Mitigate Analyte Interactions with Metal Surfaces in UHPLC. Anal. Chem. 2021, 93 (14), 5773–5781. DOI: 10.1021/ acs.analchem.0c05203 33. Todorov, T.I.; de Carmejane, O.; Walter, N. G.; Morris, M. D. Capillary Electrophoresis of RNA in Dilute and Semidilute Polymer Solutions. Electrophoresis 2001, 22 (12), 2442– 2447. DOI: 10.1002/1522‑2683(200107)22:12<2442::AID‑ ELPS2442>3.0.CO;2‑9 34. Hou, X.; Zaks, T.; Langer, R.; Dong, Y. Lipid Nanoparticles for mRNA Delivery. Nat. Rev. Mater. 2021, 6 (12), 1078–1094. DOI: 10.1038/s41578‑021‑00358‑0 35. Schoenmaker, L.; Witzigmann, D.; Kulkarni, J. A.; et al. mRNA‑Lipid Nanoparticle COVID‑19 Vaccines: Structure and Stability. Int. J. Pharm. 2021, 601, 120586. DOI: 10.1016/j. ijpharm.2021.120586 36. Fan, Y.; Marioli, M.; Zhang, K. Analytical Characteriza‑ tion of Liposomes and Other Lipid Nanoparticles for Drug Delivery. J. Pharm. Biomed. Anal. 2021, 192, 113642. DOI: 10.1016/j.jpba.2020.113642 37. Zhang, J.; Haas, R. M.; Leone, A. M. Polydispersity Charac‑ terization of Lipid Nanoparticles for siRNA Delivery Using Multiple Detection Size‑Exclusion Chromatography. Anal. Chem. 2012, 84 (14), 6088–96. DOI: 10.1021/ac3007768 38. Miroslav, L.; Holčapek, M. High‑Throughput and Compre‑ hensive Lipidomic Analysis Using Ultrahigh‑Performance Supercritical Fluid Chromatography–Mass Spectrometry. Analytical Chemistry 2015, 87 (14), 7187–7195. DOI: 10.1021/ acs.analchem.5b01054 39. Kinsey, C.; Lu, T.; Deiss, A.; et al. Determination of Lipid Content and Stability in Lipid Nanoparticles Using Ultra High‑Performance Liquid Chromatography in Combina‑ tion with a Corona Charged Aerosol Detector. Electrophore- sis 2021, 43 (9–10), 1091–1100. DOI: 10.1002/elps.202100244 40. Caputo, F.; Mehn, D.; Clogston, J. D.; et al. Asymmetric‑Flow Field‑Flow Fractionation for Measuring Particle Size, Drug Loading and (In)stability of Nanopharmaceuticals. The Joint View of European Union Nanomedicine Characteriza‑ tion Laboratory and National Cancer Institute ‑ Nanotech‑ nology Characterization Laboratory. Journal of Chromatogra- phy A 2021, 1635, 461767. DOI: 10.1016/j.chroma.2020.461767 41. Li, L.; Foley, J. P.; Helmy, R. Simultaneous Separation of Sma l l Inter fer i ng R NA a nd L ipids Usi ng Ion‑Pa i r Reversed‑Ph a se L iqu id Ch rom atog raphy. Jour nal of Chromatography A 2019, 1601, 145–154. DOI: 10.1016/j. chroma.2019.04.061. ■ Editor's Note: This article was previously published in LCGC Europe 2023 36 (2) pp. 42–49. For more podcast episodes, visit our website! Automation in Biopharma and the Impact on Workflows In this exclusive Drug Digest video interview, Pharmaceutical Technology ® editors discuss the benefits of automating entire workflows in analytics (laboratories) versus automating only specific pieces of equipment or only certain processes. What influence or impact would this have on workflows further downstream, such as clinical or commercial manufacturing? The editors interview Nick Pattinson, head of product at Automata, a London-based biotech company providing robotic automation solutions to the life sciences industry. He is a trained mechanical engineer and studied at Oxford University. Pattinson joined Automata to help make real, tangible change and help unlock the potential of scientists through automation in laboratories. Topics discussed during the interview include: • Additional automation approaches and how modular approaches fit into this • Automation opportunities in pharma (i.e., small molecule) vs. biopharma (i.e., large molecule) • Whether the level of adoption of automation differs in the industry between pharma and biopharma • How this trend toward automation in laboratory workflows impacts clinical and commercial drug development and manufacturing. For more episodes, visit our website!